- Title
- Patient-reported outcomes from the final analysis of the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: Results from the homologous recombination-deficient (HRd) and -proficient (HRp) populations
- Creators
- Floor Backes - The Ohio State UniversityMaria-Pilar Barretina-GinestaBradley Monk - Gynecologic Oncology GroupFrédéric Forget - Department of Medical Oncology, Hôpital Vivalia De Libramont, Libramont-Chevigny, BelgiumDavid O'Malley - The Ohio State UniversityNicoline Raaschou-Jensen - NSGO, Copenhagen, DenmarkLyndsay Willmott - Arizona Center for Cancer Care, Scottsdale, AZ, United StatesCarmela Pisano - Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"Roisin O'Cearbhaill - Memorial Sloan Kettering Cancer CenterPhilippe Follana - Centre Antoine Lacassagneet al.
- Publication Details
- Gynecologic oncology, Vol.208, pp.S25-S26
- Publisher
- Elsevier Inc
- Identifiers
- 991006271903902656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
Patient-reported outcomes from the final analysis of the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: Results from the homologous recombination-deficient (HRd) and -proficient (HRp) populations
Gynecologic oncology, Vol.208, pp.S25-S26
05/2026
Metrics
1 Record Views